Intrapleural injection of PD1 mAb has proven to be effective in managing MPE in mouse models and has also shown promising results in a small-scale human study, but no study was reported in non-small cell lung cancer patients with RET acquired resistance. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.